Literature DB >> 7548344

Is the use of psychotropic drugs associated with increased risk of ischemic heart disease?

K L Lapane1, S Zierler, T M Lasater, M M Barbour, R Carleton, A L Hume.   

Abstract

Earlier reports of associations between panic disorder, depression, and ischemic heart disease have not evaluated the role of the drugs used to treat these conditions. As part of a larger study on reducing cardiovascular disease in an entire community, we estimated the association between psychotropic drugs and ischemic heart disease in a large community-based population using a cohort study design. We defined exposure as current use of psychotropic medications at the time of the health interview. We determined ischemic heart disease by International Classification of Diseases, 9th revision, Clinical Modification, codes and by an epidemiologic algorithm using clinical diagnostic criteria. An elevated risk for clinically significant ischemic cardiac events was moderately associated with benzodiazepine use [relative risk (RR) = 2.0; 90% confidence interval (CI) = 1.1-3.9] and strongly associated with antidepressant use (RR = 5.7; 90% CI = 2.6-12.8), although the latter estimate was based on only six antidepressant users who had an ischemic event.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548344     DOI: 10.1097/00001648-199507000-00008

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  9 in total

1.  Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies.

Authors:  Seung-Won Oh; Joonseok Kim; Seung-Kwon Myung; Seung-Sik Hwang; Dae-Hyun Yoon
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

2.  Cardiovascular disease among people with drug use disorders.

Authors:  Birgitte Thylstrup; Thomas Clausen; Morten Hesse
Journal:  Int J Public Health       Date:  2015-06-24       Impact factor: 3.380

3.  Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study.

Authors:  D S Krantz; K S Whittaker; J L Francis; T Rutledge; B D Johnson; G Barrow; C McClure; D S Sheps; K York; C Cornell; V Bittner; V Vaccarino; W Eteiba; S Parashar; D A Vido; C N Bairey Merz
Journal:  Heart       Date:  2009-08-06       Impact factor: 5.994

4.  Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care.

Authors:  J Hippisley-Cox; M Pringle; V Hammersley; N Crown; A Wynn; A Meal; C Coupland
Journal:  BMJ       Date:  2001-09-22

5.  Exposure to tricyclic antidepressants is associated with an increased risk of incident CHD events in a population-based study.

Authors:  Leah B Rosenberg; William Whang; Daichi Shimbo; Ashish Shah; Peter A Shapiro; Karina W Davidson
Journal:  Int J Cardiol       Date:  2009-07-15       Impact factor: 4.164

6.  Should global burden of disease estimates include depression as a risk factor for coronary heart disease?

Authors:  Fiona J Charlson; Nicholas J C Stapelberg; Amanda J Baxter; Harvey A Whiteford
Journal:  BMC Med       Date:  2011-05-03       Impact factor: 8.775

7.  Use of hypnotics and the risk of or mortality from heart disease: a meta-analysis of observational studies.

Authors:  Young-Hyo Kim; Hong-Bae Kim; Do-Hyoung Kim; Ja-Young Kim; Hyun-Young Shin
Journal:  Korean J Intern Med       Date:  2017-08-28       Impact factor: 2.884

8.  Antidepressant Use and the Risk of Major Adverse Cardiovascular Events in Patients Without Known Cardiovascular Disease: A Retrospective Cohort Study.

Authors:  Ha Young Jang; Jae Hyun Kim; Yun-Kyoung Song; Ju-Young Shin; Hae-Young Lee; Yong Min Ahn; Jung Mi Oh; In-Wha Kim
Journal:  Front Pharmacol       Date:  2020-12-10       Impact factor: 5.810

9.  Impact of Antidepressants on Cardiac Events and All-Cause Mortality in Parkinson's Disease: A National Data-Linkage Study.

Authors:  Khalid Orayj
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-30       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.